Pfizer Inc., of New York, teamed up with the Alzheimer's Drug Discovery Foundation (ADDF) by way of Pfizer's Centers for Therapeutic Innovation (CTI) to advance the development of new small-molecule drugs for Alzheimer's disease and related dementias.